The effect of major adverse renal cardiovascular event (MARCE) incidence, procedure volume, and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty

Eric Keuffel, Peter A. McCullough, Thomas M. Todoran, Emmanouil S. Brilakis, Swetha R. Palli, Michael P. Ryan, Candace Gunnarsson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To determine the net economic impact of switching from low-osmolar contrast media (LOCM) to iso-osmolar contrast media (IOCM; iodixanol) in patients undergoing inpatient coronary or peripheral angioplasty in the United States (US). Methods: A budget impact model (BIM) was developed from a hospital perspective. Nationally representative procedural and contrast media prevalence rates, along with MARCE (major adverse renal cardiovascular event) incidence and episode-related cost data were derived from Premier Hospital Data (October 2014 to September 2015). A previously estimated relative risk reduction in MARCE associated with IOCM usage (9.3%) was applied. The higher cost of IOCM was included when calculating the net impact estimates at the aggregate, hospital type, and per hospital levels. One-way (±25%) and probabilistic sensitivity analyses identified the model’s most important inputs. Results: Based on weighted analysis, 513,882 US inpatient angioplasties and 35,610 MARCE cases were estimated annually. Switching to an “IOCM only” strategy from a “LOCM only” strategy increases contrast media cost, but prevents 2,900 MARCE events. The annual budget impact was an estimated saving of $30.71 million, aggregated across all US hospitals, $6,316 per hospital, or $60 per procedure. Net savings were maintained across all univariate sensitivity analyses. While MARCE/event-free cost differential was the most important factor driving total net savings for hospitals in the Northeast and West, procedural volume was important in the Midwest and rural locations. Conclusions: Switching to an “IOCM only” strategy from a “LOCM only” approach yields substantial net global savings to hospitals, both at the national level and within hospital sub-groups. Hospital administrators should maintain awareness of the factors that are likely to be more influential for their hospital and recognize that purchasing on the basis of lower contrast media cost may result in higher overall costs for patients undergoing inpatient angioplasty.

Original languageEnglish (US)
Pages (from-to)356-364
Number of pages9
JournalJournal of Medical Economics
Volume21
Issue number4
DOIs
StatePublished - Apr 3 2018

Fingerprint

Hospital Costs
Angioplasty
Contrast Media
Inpatients
Kidney
Incidence
Costs and Cost Analysis
Budgets
Hospital Purchasings
Hospital Administrators
State Hospitals
Risk Reduction Behavior
Economics

Keywords

  • Angioplasty
  • budget impact model
  • contrast media
  • iso-osmolar contrast media
  • low-osmolar contrast media
  • major adverse renal cardiovascular event
  • Visipaque

ASJC Scopus subject areas

  • Health Policy

Cite this

The effect of major adverse renal cardiovascular event (MARCE) incidence, procedure volume, and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty. / Keuffel, Eric; McCullough, Peter A.; Todoran, Thomas M.; Brilakis, Emmanouil S.; Palli, Swetha R.; Ryan, Michael P.; Gunnarsson, Candace.

In: Journal of Medical Economics, Vol. 21, No. 4, 03.04.2018, p. 356-364.

Research output: Contribution to journalArticle

Keuffel, Eric ; McCullough, Peter A. ; Todoran, Thomas M. ; Brilakis, Emmanouil S. ; Palli, Swetha R. ; Ryan, Michael P. ; Gunnarsson, Candace. / The effect of major adverse renal cardiovascular event (MARCE) incidence, procedure volume, and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty. In: Journal of Medical Economics. 2018 ; Vol. 21, No. 4. pp. 356-364.
@article{6759be139b4f487babdf98032e8ec72f,
title = "The effect of major adverse renal cardiovascular event (MARCE) incidence, procedure volume, and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty",
abstract = "Objective: To determine the net economic impact of switching from low-osmolar contrast media (LOCM) to iso-osmolar contrast media (IOCM; iodixanol) in patients undergoing inpatient coronary or peripheral angioplasty in the United States (US). Methods: A budget impact model (BIM) was developed from a hospital perspective. Nationally representative procedural and contrast media prevalence rates, along with MARCE (major adverse renal cardiovascular event) incidence and episode-related cost data were derived from Premier Hospital Data (October 2014 to September 2015). A previously estimated relative risk reduction in MARCE associated with IOCM usage (9.3{\%}) was applied. The higher cost of IOCM was included when calculating the net impact estimates at the aggregate, hospital type, and per hospital levels. One-way (±25{\%}) and probabilistic sensitivity analyses identified the model’s most important inputs. Results: Based on weighted analysis, 513,882 US inpatient angioplasties and 35,610 MARCE cases were estimated annually. Switching to an “IOCM only” strategy from a “LOCM only” strategy increases contrast media cost, but prevents 2,900 MARCE events. The annual budget impact was an estimated saving of $30.71 million, aggregated across all US hospitals, $6,316 per hospital, or $60 per procedure. Net savings were maintained across all univariate sensitivity analyses. While MARCE/event-free cost differential was the most important factor driving total net savings for hospitals in the Northeast and West, procedural volume was important in the Midwest and rural locations. Conclusions: Switching to an “IOCM only” strategy from a “LOCM only” approach yields substantial net global savings to hospitals, both at the national level and within hospital sub-groups. Hospital administrators should maintain awareness of the factors that are likely to be more influential for their hospital and recognize that purchasing on the basis of lower contrast media cost may result in higher overall costs for patients undergoing inpatient angioplasty.",
keywords = "Angioplasty, budget impact model, contrast media, iso-osmolar contrast media, low-osmolar contrast media, major adverse renal cardiovascular event, Visipaque",
author = "Eric Keuffel and McCullough, {Peter A.} and Todoran, {Thomas M.} and Brilakis, {Emmanouil S.} and Palli, {Swetha R.} and Ryan, {Michael P.} and Candace Gunnarsson",
year = "2018",
month = "4",
day = "3",
doi = "10.1080/13696998.2017.1415912",
language = "English (US)",
volume = "21",
pages = "356--364",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The effect of major adverse renal cardiovascular event (MARCE) incidence, procedure volume, and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty

AU - Keuffel, Eric

AU - McCullough, Peter A.

AU - Todoran, Thomas M.

AU - Brilakis, Emmanouil S.

AU - Palli, Swetha R.

AU - Ryan, Michael P.

AU - Gunnarsson, Candace

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Objective: To determine the net economic impact of switching from low-osmolar contrast media (LOCM) to iso-osmolar contrast media (IOCM; iodixanol) in patients undergoing inpatient coronary or peripheral angioplasty in the United States (US). Methods: A budget impact model (BIM) was developed from a hospital perspective. Nationally representative procedural and contrast media prevalence rates, along with MARCE (major adverse renal cardiovascular event) incidence and episode-related cost data were derived from Premier Hospital Data (October 2014 to September 2015). A previously estimated relative risk reduction in MARCE associated with IOCM usage (9.3%) was applied. The higher cost of IOCM was included when calculating the net impact estimates at the aggregate, hospital type, and per hospital levels. One-way (±25%) and probabilistic sensitivity analyses identified the model’s most important inputs. Results: Based on weighted analysis, 513,882 US inpatient angioplasties and 35,610 MARCE cases were estimated annually. Switching to an “IOCM only” strategy from a “LOCM only” strategy increases contrast media cost, but prevents 2,900 MARCE events. The annual budget impact was an estimated saving of $30.71 million, aggregated across all US hospitals, $6,316 per hospital, or $60 per procedure. Net savings were maintained across all univariate sensitivity analyses. While MARCE/event-free cost differential was the most important factor driving total net savings for hospitals in the Northeast and West, procedural volume was important in the Midwest and rural locations. Conclusions: Switching to an “IOCM only” strategy from a “LOCM only” approach yields substantial net global savings to hospitals, both at the national level and within hospital sub-groups. Hospital administrators should maintain awareness of the factors that are likely to be more influential for their hospital and recognize that purchasing on the basis of lower contrast media cost may result in higher overall costs for patients undergoing inpatient angioplasty.

AB - Objective: To determine the net economic impact of switching from low-osmolar contrast media (LOCM) to iso-osmolar contrast media (IOCM; iodixanol) in patients undergoing inpatient coronary or peripheral angioplasty in the United States (US). Methods: A budget impact model (BIM) was developed from a hospital perspective. Nationally representative procedural and contrast media prevalence rates, along with MARCE (major adverse renal cardiovascular event) incidence and episode-related cost data were derived from Premier Hospital Data (October 2014 to September 2015). A previously estimated relative risk reduction in MARCE associated with IOCM usage (9.3%) was applied. The higher cost of IOCM was included when calculating the net impact estimates at the aggregate, hospital type, and per hospital levels. One-way (±25%) and probabilistic sensitivity analyses identified the model’s most important inputs. Results: Based on weighted analysis, 513,882 US inpatient angioplasties and 35,610 MARCE cases were estimated annually. Switching to an “IOCM only” strategy from a “LOCM only” strategy increases contrast media cost, but prevents 2,900 MARCE events. The annual budget impact was an estimated saving of $30.71 million, aggregated across all US hospitals, $6,316 per hospital, or $60 per procedure. Net savings were maintained across all univariate sensitivity analyses. While MARCE/event-free cost differential was the most important factor driving total net savings for hospitals in the Northeast and West, procedural volume was important in the Midwest and rural locations. Conclusions: Switching to an “IOCM only” strategy from a “LOCM only” approach yields substantial net global savings to hospitals, both at the national level and within hospital sub-groups. Hospital administrators should maintain awareness of the factors that are likely to be more influential for their hospital and recognize that purchasing on the basis of lower contrast media cost may result in higher overall costs for patients undergoing inpatient angioplasty.

KW - Angioplasty

KW - budget impact model

KW - contrast media

KW - iso-osmolar contrast media

KW - low-osmolar contrast media

KW - major adverse renal cardiovascular event

KW - Visipaque

UR - http://www.scopus.com/inward/record.url?scp=85044089700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044089700&partnerID=8YFLogxK

U2 - 10.1080/13696998.2017.1415912

DO - 10.1080/13696998.2017.1415912

M3 - Article

C2 - 29226736

AN - SCOPUS:85044089700

VL - 21

SP - 356

EP - 364

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 4

ER -